Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Diseases, Genetic

ClinicalTrials.gov lists 2,378 trials for Skin Diseases, Genetic or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 58.

MeSH D012873 Congenital / Hereditary / Neonatal C16 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 242 Phase 1/2 Phase 1/2 100 Phase 2 Phase 2 463 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 290 Phase 4 Phase 4 160 Not applicable Not applicable 529 Observational Observational 555 Phase 1 Phase 1 242 Phase 1/2 Phase 1/2 100 Phase 2 Phase 2 463 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 290 Phase 4 Phase 4 160 Not applicable Not applicable 529 Observational Observational 555

Trials per phase

1 more section with rows

25 of the 2,378 trials are tagged with Skin Diseases, Genetic itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Diseases, Genetic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Diseases, Genetic trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 189

1992: 1 trials (Observational 1) 1993: 1 trials (Phase 1/2 1) 1994: 3 trials (Observational 2, Phase 2 1) 1995: 2 trials (Observational 2) 1996: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 1997: 2 trials (Observational 2) 1998: 2 trials (Observational 1, Phase 3 1) 1999: 6 trials (Observational 3, Not applicable 1, Phase 2/3 1, Phase 2 1) 2000: 10 trials (Observational 5, Phase 2 3, Phase 1/2 1, Phase 1 1) 2001: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3) 2002: 10 trials (Observational 3, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2 1) 2003: 15 trials (Observational 2, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1) 2004: 39 trials (Observational 8, Not applicable 4, Phase 4 13, Phase 3 10, Phase 2 1, Phase 1/2 1, Phase 1 2) 2005: 38 trials (Observational 11, Not applicable 4, Phase 4 10, Phase 3 3, Phase 2 5, Phase 1/2 2, Phase 1 3) 2006: 29 trials (Observational 7, Not applicable 2, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 13, Phase 1 1) 2007: 40 trials (Observational 9, Not applicable 4, Phase 4 9, Phase 3 7, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 2) 2008: 39 trials (Observational 8, Not applicable 3, Phase 4 8, Phase 3 6, Phase 2 6, Phase 1/2 3, Phase 1 5) 2009: 70 trials (Observational 18, Not applicable 11, Phase 4 10, Phase 3 5, Phase 2 20, Phase 1/2 2, Phase 1 4) 2010: 57 trials (Observational 9, Not applicable 15, Phase 4 7, Phase 3 7, Phase 2/3 2, Phase 2 10, Phase 1/2 6, Phase 1 1) 2011: 78 trials (Observational 24, Not applicable 25, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 7) 2012: 64 trials (Observational 12, Not applicable 16, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 14, Phase 1/2 2, Phase 1 7) 2013: 54 trials (Observational 14, Not applicable 12, Phase 4 2, Phase 3 3, Phase 2 19, Phase 1/2 3, Phase 1 1) 2014: 80 trials (Observational 19, Not applicable 19, Phase 4 2, Phase 3 12, Phase 2 16, Phase 1/2 2, Phase 1 10) 2015: 89 trials (Observational 18, Not applicable 14, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 24, Phase 1/2 3, Phase 1 17) 2016: 87 trials (Observational 16, Not applicable 23, Phase 4 3, Phase 3 6, Phase 2 23, Phase 1/2 7, Phase 1 9) 2017: 98 trials (Observational 26, Not applicable 22, Phase 4 4, Phase 3 10, Phase 2/3 1, Phase 2 21, Phase 1/2 5, Phase 1 9) 2018: 148 trials (Observational 31, Not applicable 30, Phase 4 7, Phase 3 29, Phase 2/3 1, Phase 2 29, Phase 1/2 7, Phase 1 14) 2019: 147 trials (Observational 35, Not applicable 34, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 34, Phase 1/2 4, Phase 1 19) 2020: 140 trials (Observational 37, Not applicable 28, Phase 4 9, Phase 3 19, Phase 2/3 4, Phase 2 28, Phase 1/2 9, Phase 1 6) 2021: 144 trials (Observational 45, Not applicable 28, Phase 4 4, Phase 3 13, Phase 2/3 1, Phase 2 30, Phase 1/2 7, Phase 1 16) 2022: 166 trials (Observational 35, Not applicable 47, Phase 4 10, Phase 3 21, Phase 2/3 3, Phase 2 26, Phase 1/2 6, Phase 1 18) 2023: 189 trials (Observational 44, Not applicable 50, Phase 4 14, Phase 3 24, Phase 2/3 4, Phase 2 27, Phase 1/2 7, Phase 1 19) 2024: 168 trials (Observational 34, Not applicable 47, Phase 4 3, Phase 3 26, Phase 2/3 1, Phase 2 29, Phase 1/2 5, Phase 1 23) 2025: 169 trials (Observational 39, Not applicable 38, Phase 4 4, Phase 3 20, Phase 2/3 3, Phase 2 36, Phase 1/2 3, Phase 1 26)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 157
2025 169
2024 168
2023 189
2022 166
2021 144
2020 140
2019 147
2018 148
2017 98

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 180 trials starting in 2026 and about 170 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 216 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 1,518 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Diseases, Genetic trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 242
Phase 1/2 100
Phase 2 463
Phase 2/3 31
Phase 3 290
Phase 4 160
Not applicable 529
Observational 555
Expanded access 8

How many Skin Diseases, Genetic trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 107
Recruiting 282
Enrolling by invitation 20
Active, not recruiting 107
Available 5

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Diseases, Genetic trials? (12)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 58
National Institute of Allergy and Infectious Diseases (NIAID) 41
LEO Pharma 37
Sanofi 36
AbbVie 32

Showing 5 of 12 sponsors.

Start your 14-day trial Email me all 12 sponsors as a PDF

Which drugs are being tested for Skin Diseases, Genetic? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Abrocitinib 28
Pimecrolimus 20
Tralokinumab 18
Rocatinlimab 12
Nemolizumab 12

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dupilumab/Dupixent 78
Vehicle Cream 25
Lebrikizumab Pen 24
upadacitinib 15mg/day 23
IR Tacrolimus 20

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Diseases, Genetic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Dermatitis atopic 201 60
Pneumonia 127 48
Asthma 124 38
Gastroenteritis 65 9
Cellulitis 57 36

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Diseases, Genetic? (24)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA 2023 Yes
Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops. Ophthalmology 2022 Yes
Arterial Tortuosity and Its Correlation with White Matter Hyperintensities in Acute Ischemic Stroke. Neural plasticity 2022 Yes
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation. Journal of pediatric hematology/oncology 2021 Yes
Peeling Skin Disorders: A Paradigm for Skin Desquamation. The Journal of investigative dermatology 2018 Yes

Showing 5 of 24 publications.

Start your 14-day trial Email me all 24 publications as a PDF

Sub-conditions in MeSH (29)

MeSH descendants one level down with at least one trial, most trials first.

+19 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages